News Snapshot:
A man works in the laboratory of Chinese vaccine maker Sinovac Biotech, developing an experimental vaccine. Singapore / Beijing: Synovac Biotech’s experimental COVID-19 vaccine, CoronaVac, triggered an accelerated immune response, but the level of antibodies produced was lower than those who recovered from the disease, preliminary testing results showed Wednesday. Although the first mid-term trials were not designed to assess the effectiveness of Coronavac, the researchers said it could provide adequate protection, based on their experience with other vaccines and data. preclinical studies on macaques. . U.S. drugmakers Pfizer and Morden, along with Russia, warmed up this month’s study on...
